Company news

Cynata Therapeutics Limited news in 2023

Cynata Therapeutics Limited's news releases, calls and decks from 2023, newest first.

View company

Recruitment Completed in Phase 3 OA Clinical Trial

December 12, 2023

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

December 6, 2023

Cynata Receives $2.315m R&D Tax Incentive Refund

November 13, 2023

Approval of Clinical Trial of CYP-001 in Kidney Transplant

August 20, 2023

Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment

August 9, 2023

Strategic Review of Cynata Clinical Development Portfolio

July 24, 2023

Cynata announces CEO succession and Board changes

June 29, 2023

Cynata Completes Oversubscribed Share Purchase Plan

May 10, 2023

Share Purchase Plan Booklet & Option Prospectus

April 19, 2023

Ethics Committee Approval for Proposed aGvHD Phase 2 Trial

April 11, 2023

Capital Raising Presentation

April 5, 2023

Cynata completes $5.0m Placement and launches SPP

April 5, 2023

Cynata Adds New Sites for DFU Clinical Trial

March 16, 2023

Cynata Receives IRB Approval for aGvHD Clinical Trial

January 29, 2023

Notice of Acceptance for Cynata Australian Patent

January 9, 2023

Decks in 2023